NCT06747299View on ClinicalTrials.gov

The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study

Not yet recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
T-NK Cell Lymphoma
Trial Locations (1)

Unknown

Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine, Shanghai

All Listed Sponsors
collaborator

West China Hospital

OTHER

lead

Ruijin Hospital

OTHER

NCT06747299 - The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study | Biotech Hunter | Biotech Hunter